Nosocomial Infections and Role of Nanotechnology

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Vishwanath Managuli	+ 1967 word(s)	1967	2022-02-09 04:49:09	\|
2	format correct	Catherine Yang	-14 word(s)	1953	2022-02-09 06:46:05	\|

This entry is adapted from the peer-reviewed paper 10.3390/bioengineering9020051

Nosocomial infections, termed hospital-acquired infections (HAIs), are acquired from a healthcare or hospital setting. HAI is mainly caused by bacteria, such as Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, Enterococci spp., Methicillin-resistant Staphylococcus aureus (MRSA), and many more. Due to growing antibacterial resistance, nanotechnology has paved the way for more potent and sensitive methods of detecting and treating bacterial infections.

hospital-acquired infections nanotechnology Nosocomial Infections Healthcare Multi-Drug Resistance

1. Introduction

The term ‘nosocomial’ is derived from two Greek words, ‘nosus’ and ‘komeion’ that literally translate into ‘disease’, and ‘take care of’. It was during the first half of the 18th century that the scientific study of nosocomial infection or hospital-acquired infection (HAI) started ^[1]. During the post-World War II era, various antibiotics were discovered and widely used in treatment. Penicillin was used extensively, which caused the death rate due to postoperative pneumonia to reduce from 30% to <10% and surgical wound infections to reduce below 5%. By the 1960s, the surgical infection rate reduced below 2% due to the introduction of other antibiotics ^[2]. However, this soon led to a major penicillin-resistant Staphylococcal epidemic amongst patients and health care workers and many of them were nasal and dermal carriers ^[3]. After the discovery of methicillin and vancomycin in the 1960s, the emergence of methicillin-resistant Staphylococcus aureus (MRSA) began due to overuse. Along with MRSA, other resistant organisms that emerged were vancomycin-resistant Enterococcus spp., a few members of the Enterobacteriaceae family, Pseudomonas aeruginosa, Streptococcus spp., and Candida spp. Hence, nosocomial infections are infections that occur in a patient while receiving care in a hospital or other health care facility ^[4]. After an infection is confirmed to be of nosocomial origin, according to the definition mentioned before, the specific type of infection is categorized based on the systemic classification provided by the National Health Safety Network (NHSN) with the Centers for Disease Control and Prevention (CDC) which are specifically based on clinical and biological criteria ^[5]. According to the NHSN and CDC criteria, HAIs have been classified into 14 different types. Out of these, the incidences of device associated HAIs (DA-HAI) are the most common in healthcare settings which include central-line associated bloodstream infections (CLABSI), catheter-related bloodstream infections (CRBSI), catheter-associated urinary tract infections (CAUTI), ventilator-associated pneumonia (VAP), and surgical site infections (SSI) ^[6]. The most common nosocomial infection-causing bacteria include S. aureus, including antibiotic-resistant MRSA, Escherichia coli, Enterococcus spp., and Candida spp. With the increase in antibiotic resistance of nosocomial infections, nanoparticles, especially metallic nanoparticles, provide a successful alternative due to their special properties including high reactivity and stability. Nanoparticles increase the permeability of bacterial cell membranes, resulting in a higher uptake of antibiotics by the bacterial cells ^[7].

2. Nano Strategies Combating Nosocomial Infections

The development of antibiotic resistance is a rising crisis today. Further, genetic tolerance against antibiotics in bacteria such as MRSA is a common occurrence. Nanomaterials inhibit bacterial growth or activity that results in infections. Nanoparticles penetrate the bacteria and biofilm leading to reactive oxygen species (ROS) generation that eliminates bacteria. Thus, nanoparticles are a novel approach to combat drug-resistant bacterial infections. Different nanomaterials, such as nanoparticles and nanotubes, are directly used in biomedical devices to prevent spreading infections.

Owing to the small size and high surface area to volume ratio, nanoparticles (NPs) have a much stronger physical interaction capability with bacterial cells compared to microparticles. These NPs offer many interaction mechanisms between nanomaterials and cell walls, such as changing the membrane permeability by penetration, blocking oxidative phosphorylation, or by generating free radicals leading to damage of the cell membrane, and in turn cell death, thus increasing the oxidative stress and destroying DNA ^[8], as shown in Figure 1. Additionally, the ionic activity of nanoparticles can modulate the bacterial signal transduction leading to the inhibition of bacterial growth or inactivating the enzymes by interacting with them. There are physical interaction mechanisms too, which include bacterial wrapping to induce surface stresses and penetration through sharp edges that causes physical damage and adverse chemical effects ^[9]^[10]. Similarly, helpful is the creation of anti-adhesion surfaces that inhibit biofilm formation ^[11].

Figure 1. Mechanisms of nanoparticle action in bacterial cells include changing membrane permeability and the generation of free radicals leading to DNA and protein damage. Adapted from Wang et al., 2017, Copyright 2017 Informa PLC ^[12].

2.1. Nanoparticles Based Molecular Beacons

Nanoparticles can be used as molecular beacons to identify relevant bacterial strains in minimal time ^[13]^[14]^[15]^[16]^[17]^[18]. This is especially important in emergency cases or in an ICU where immediate results are required to continue medical procedures. Molecular beacons are the most promising method for qualitative and quantitative biological detection of bacteria. In a recent study, molecular beacons loaded with nanoparticles have been used for the rapid detection of bacteria and viruses (Figure 2a). In another recent study, it was observed that hybridizing molecular beacons with nanoparticles improved the bacterial efficiency. The new age nanoprobes comprised of molecular beacons hybridized to gold nanoparticles could detect E. coli at a concentration of 10² cfu/mL. This method was 1000 times more sensitive than detecting using only molecular beacons ^[13].

Figure 2. Mechanisms of nanoparticles combating nosocomial infections: (a) nanoparticles as molecular beacons, (b) nanoparticles for targeted drug delivery of antibiotics, and (c) types of nanoparticles preventing biofilm-associated nosocomial infections.

Various NPs are employed in life science to accurately detect a bacterial strain using the following techniques: Surface-enhanced Raman Spectroscopy (SERS) detection method, the rapid and cost-effective immuno-magnetic separation technique, and short detection time-based fluorescence microscopy, as well as fast and visual methods like the calorimetric method or highly sensitive methods like real-time PCR techniques ^[8]^[14]^[15]. In sandwich-structure immunoassays, E. coli and S. aureus were detected using the SERS method in a total assay time of 10 min ^[16]. Similarly, in another study, E. coli and S. epidermidis were detected using the SERS method in 10 min by employing the synthesis of AgNPs coating on the cell wall of bacteria ^[17]. This leads to the 30 times increase in the Raman signal of these bacteria compared to that obtained using a mixing of colloid and bacterial suspension. Additionally, reports are showing the presence of cost-friendly techniques to detect bloodstream infection using magneto fluorescent NPs which proved to be time-saving and equally sensitive methods ^[18]. Apart from this, the inherent superiority of molecular beacon probes and biofunctionalized NPs led to a series of novel principles, methods, and techniques to exploit bioanalytical and biomedical studies as well.

2.2. Nanoparticles Formulated with Drugs and Antibiotics-Nano Bactericidal

Nanomedicine is an offshoot of nanotechnology under exploration for its suitability in the delivery of treatment and healthcare benefits. It provides platforms like targeted drug delivery using different nanoparticulate systems, a multidrug complex entrapped in a single nanoparticle, surface functionalization with nano-particulate antibiotic materials, nano antibiotics, and creating ROS using inorganic metal oxide NPs, playing important roles in the restoration of antibiotic activity (Figure 2c) ^[19]^[20]. Antibiotics conjugated with NPs give the advantage of lower sample consumption and higher sensitivity ^[21]. Studies have reported that nanoparticles coupled with antibiotics, such as vancomycin, amoxicillin, and penicillin G, show an enhanced antimicrobial resistance against S. aureus and E. coli ^[22]. NO (Nitric oxide) releasing nanoparticles and metal oxide nanoparticles (TiO₂, ZnO) have also shown effective antimicrobial activity against many MDR strains and are under exploration ^[8]. In a recent study, gold nanoparticles (Au NPs) were conjugated with ceragenin CSA-131 (cationic steroid antimicrobial) and were tested for their bactericidal activity against S. aureus, S. epidermidis, K. pneumoniae, K. oxytoca, and P. aeruginosa. All nanosystems exhibited potent bactericidal activity by generating ROS, resulting in the damage of the bacterial membranes and the leakage of intracellular content ^[23]. Researchers have taken an interest in exploring the suitability of nano-photo thermal therapy for MDR bacteria. This therapy involves the selective killing of bacteria by the transfer of heat generated from the conversion of electromagnetic radiation. It irreversibly damages the bacterial membranes and interferes with cell wall biosynthesis. These outcomes are a boon to researchers as antibiotics are turning out to be inefficient ^[23]^[24].

2.3. Nanotechnology in the Development of Drug Delivery Systems (Nano-DDS)

Drugs with poor solubility and absorption ability can be delivered via nanoparticles for target-specific drug delivery. However, the efficacy of these nanoparticles for drug delivery depends on factors such as size, shape, and other physical/chemical characteristics ^[25]. Malachite green (MG) encapsulated in mesoporous silica nanoparticles (MSN) was tested against common nosocomial infection-causing bacteria such as S. aureus and E. coli. MG-MSN was found to be effective against both tested bacterial strains. S. aureus was more phototoxic to MG-MSN compared to E. coli. The anti-biofilm efficacy of MG-MSN on E. coli and S. aureus were also studied. Biofilm inhibition was found to be 65.68 ± 2.62% in E. coli and 79.66 ± 3.82% in S. aureus ^[26]. Nano-DDS is a promising approach in the control of HCAI, but only a small number of nano-DDS products were commercially successful in the market ^[27]^[28]. This is mostly due to financial profitability and poor information about product functioning available to health professionals across countries, leading to further delay in its full exploitation concerning generic medicine. Similarly, concerns about the toxicity of nanoparticles, their effect on the blood-brain barrier, and their delivery to the central nervous system are limiting their application in medicine. Industrial production, quality control, and storage stability of nanoparticles must be assessed to ensure their purity and safe administration in a biological system ^[29]. Nevertheless, the progress of the research in this domain promises a higher success ratio in defending the patient’s interests.

2.4. Surface Modifications to Control Biofilm-Associated Infections

Biofilm-based infections are important causes of morbidity, affecting millions of people every year, typically causing chronic nosocomial infections. The current clinical practice with biofilm-associated infection is to treat it with high-dose antibiotics and if symptoms persist, a surgical replacement can be done to reduce further complications to patient health ^[30]. Tailoring the functional surface properties of implants or biomedical devices used during treatments can curb the initial and later stages of infection development. Nanoparticles facilitate the sustained release of attached bioactive materials or ions and thus provide longer antibiofilm activity. In a study conducted on the antibacterial activity of silver nanoparticles (AgNPs) against nosocomial A. baumannii AIIMS 7 in biofilm mode, nanoparticles exhibited significant biofilm disruption activity at a minimum inhibitory concentration of 2 mg/mL. The eradication of the biofilm was improved on combined exposure to AgNPs and antibiotics. These nanoparticles inhibited bacterial growth through intracellular oxidative stress and interact with thiol-groups in cellular proteins resulting in denaturation ^[31]. Similarly, surface modification of other nanoparticles such as AuNPs makes them desirable to be used for oral biology ^[32] and other healthcare applications.

Methodologies like anti-fouling, anti-adhesive or bactericidal coating, and many more methods are adopted for reducing bacterial adhesion on medical devices ^[30]^[33]. These multifunctional coatings simultaneously promote osseointegration and prevent infection of implants. Silver is the most common bactericidal agent used to date due to its broad spectrum of antimicrobial activity against both Gram-positive and negative bacterial strains ^[33]. The inorganic nanoparticles of Ag and Au were used in coating urethral ^[34], venous and ventricular catheters ^[35], organic nanoparticles based on chitosan and PEG stabilized lipid in bone and dental implants ^[36], as well as several other metallic/metal-polymer composites in the development of face masks, heart valves, pedicle screws, contact lenses, and orthopedic and oral implants depending on a working mechanism ^[37].

To address the looming threat of nosocomial infection spread, there is an urgent need for a comprehensive action plan at the national and international levels. An independent review by a committee sponsored and supported by Wellcome Trust and the Department of Health, UK provides a deeper insight and solutions. HAI account for 0.7 million deaths globally, causes the death of nearly 60,000 newborns in India each year, two million infections in the USA alone, and caused 20 billion USD in excess costs. Additionally, the death toll may increase to 10 million by 2050. Therefore, the committee came up with a suggestion of tackling antimicrobial resistance on ten different fronts ^[38]. The list includes Public Awareness, Surveillance, Human Capital, Vaccines and Alternatives, a Global Innovation Fund, Rapid Diagnostics kits to guide doctors, and an International Coalition for action, etc. In this way, nanotechnology can play a major role and offer solutions in rapid diagnostics, control of the spread, and vaccine effectiveness.

References

Forder, A.A. A brief history of infection control-past and present. S. Afr. Med. J. 2007, 97, 1161–1164.
Available online: https://www.optimus-ise.com/historical/history-of-hospital-infections/ (accessed on 29 August 2021).
Selwyn, S. Changing patterns in hospital infection. Nurs. Times 1972, 68, 643–646.
Voidazan, S.; Albu, S.; Toth, R.; Grigorescu, B.; Rachita, A.; Moldovan, I. Healthcare Associated Infections—A New Pathology in Medical Practice? Int. J. Environ. Res. 2020, 17, 760.
CDC/NHSN Surveillance Definitions for Specific Types of Infections. IOP Publishing CDC Website. Available online: https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf (accessed on 14 September 2021).
Septimus, E.J.; Moody, J. Prevention of device-related healthcare-associated infections. F1000Research 2016, 5, 65.
Amaro, F.; Morón, Á.; Díaz, S.; Martín-González, A.; Gutiérrez, J.C. Metallic Nanoparticles—Friends or Foes in the Battle against Antibiotic-Resistant Bacteria? Microorganisms 2021, 9, 364.
Singh, R.; Smitha, M.S.; Singh, S.P. The role of nanotechnology in combating multi-drug resistant bacteria. J. Nanosci. Nanotechnol. 2014, 14, 4745–4756.
Pandit, S.; Gaska, K.; Kádár, R.; Mijakovic, I. Graphene-Based Antimicrobial Biomedical Surfaces. ChemPhysChem 2021, 22, 250–263.
Pandit, S.; Cao, Z.; Mokkapati, V.R.; Celauro, E.; Yurgens, A.; Lovmar, M.; Westerlund, F.; Sun, J.; Mijakovic, I. Vertically aligned graphene coating is bactericidal and prevents the formation of bacterial biofilms. Adv. Mater. Interfaces 2018, 5, 1701331.
Bregnocchi, A.; Zanni, E.; Uccelletti, D.; Marra, F.; Cavallini, D.; De Angelis, F.; De Bellis, G.; Bossù, M.; Ierardo, G.; Polimeni, A.; et al. Graphene-based dental adhesive with anti-biofilm activity. J. Nanobiotechnol. 2017, 15, 89.
Wang, L.; Hu, C.; Shao, L. The antimicrobial activity of nanoparticles: Present situation and prospects for the future. Int. J. Nanomed. 2017, 12, 1227–1249.
Cao, J.; Feng, C.; Liu, Y.; Wang, S.; Liu, F. Highly sensitive and rapid bacteria detection using molecular beacon–Au nanoparticles hybrid nanoprobes. Biosens. Bioelectron. 2014, 57, 133–138.
Raj, V.; Vijayan, A.N.; Joseph, K. Cysteine capped gold nanoparticles for naked eye detection of E. coli bacteria in UTI patients. Sens. Biosens. Res. 2015, 5, 33–36.
Mocan, T.; Matea, C.T.; Pop, T.; Mosteanu, O.; Buzoianu, A.D.; Puja, C.; Lancu, C.; Mocan, L. Development of nanoparticle-based optical sensors for pathogenic bacterial detection. J. Nanobiotechnol. 2017, 15, 25.
Wang, C.; Wang, J.; Li, M.; Qu, X.; Zhang, K.; Rong, Z.; Xiao, R.; Wang, S. A rapid SERS method for label-free bacteria detection using polyethylenimine-modified Au-coated magnetic microspheres and Ag nanoparticles. Analyst 2016, 141, 6226–6238.
Zhou, H.; Yang, D.; Ivleva, N.P.; Mircescu, N.E.; Niessner, R.; Haisch, C. SERS detection of bacteria in water by in situ coating with Ag nanoparticles. Anal. Chem. 2014, 86, 1525–1533.
Gao, J.; Li, L.; Ho, P.L.; Mak, G.C.; Gu, H.; Xu, B.J. Combining fluorescent probes and biofunctional magnetic nanoparticles for rapid detection of bacteria in human blood. Adv. Mater. 2006, 18, 3145–3148.
Shimanovich, U.; Gedanken, A. Nanotechnology solutions to restore antibiotic activity. J. Mater. Chem. 2016, 4, 824–833.
Panáček, A.; Smékalová, M.; Večeřová, R.; Bogdanová, K.; Röderová, M.; Kolář, M.; Kilianová, M.; Hradilová, Š.; Froning, J.P.; Havrdová, M.; et al. Silver nanoparticles strongly enhance and restore bactericidal activity of inactive antibiotics against multiresistant Enterobacteriaceae. Colloids Surf. B Biointerfaces 2016, 142, 392–399.
Roy, A.S.; Parveen, A.; Koppalkar, A.R.; Prasad, M.A. Effect of nano-titanium dioxide with different antibiotics against methicillin-resistant Staphylococcus aureus. J. Biomater. Nanobiotechnol. 2010, 1, 37–41.
Shahverdi, A.R.; Fakhimi, A.; Shahverdi, H.R.; Minaian, S. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomed. Nanotechnol. Biol. Med. 2007, 3, 168–171.
Chmielewska, S.J.; Skłodowski, K.; Depciuch, J.; Deptuła, P.; Piktel, E.; Fiedoruk, K.; Kot, P.; Paprocka, P.; Fortunka, K.; Wollny, T.; et al. Bactericidal properties of rod-, peanut-, and star-shaped gold nanoparticles coated with ceragenin CSA-131 against multidrug-resistant bacterial strains. Pharmaceutics 2021, 13, 425.
Qing, G.; Zhao, X.; Gong, N.; Chen, J.; Li, X.; Gan, Y.; Wang, Y.; Zhang, Z.; Zhang, Y.; Guo, W.; et al. Thermo-responsive triple-function nanotransporter for efficient chemo-photothermal therapy of multidrug-resistant bacterial infection. Nat. Commun. 2019, 10, 4336.
Patra, J.K.; Das, G.; Fraceto, L.F.; Campos, E.V.; del Pilar Rodriguez-Torres, M.; Acosta-Torres, L.S.; Diaz-Torres, L.A.; Grillo, R.; Swamy, M.K.; Sharma, S.; et al. Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnol. 2018, 16, 71.
Paramanantham, P.; Siddhardha, B.; Sb, S.L.; Sharan, A.; Alyousef, A.A.; Al Dosary, M.S.; Arshad, M.; Syed, A. Antimicrobial photodynamic therapy on Staphylococcus aureus and Escherichia coli using malachite green encapsulated mesoporous silica nanoparticles: An in vitro study. PeerJ. 2019, 7, e7454.
Ranghar, S.; Sirohi, P.; Verma, P.; Agarwal, V. Nanoparticle-based drug delivery systems: Promising approaches against infections. Braz. Arch. Biol. Technol. 2014, 57, 209–222.
Ramos, M.A.; Da Silva, P.B.; Spósito, L.; De Toledo, L.G.; Bonifácio, B.V.; Rodero, C.F.; Dos Santos, K.C.; Chorilli, M.; Bauab, T.M. Nanotechnology-based drug delivery systems for control of microbial biofilms: A review. Int. J. Nanomed. 2018, 13, 1179.
Zhang, T.T.; Li, W.; Meng, G.; Wang, P.; Liao, W. Strategies for transporting nanoparticles across the blood–brain barrier. Biomater. Sci. 2016, 4, 219–229.
Khatoon, Z.; McTiernan, C.D.; Suuronen, E.J.; Mah, T.F.; Alarcon, E.I. Bacterial biofilm formation on implantable devices and approaches to its treatment and prevention. Heliyon 2018, 4, e01067.
Singh, R.; Vora, J.; Nadhe, S.B.; Wadhwani, S.A.; Shedbalkar, U.U.; Chopade, B.A. Antibacterial activities of bacteriagenic silver nanoparticles against nosocomial Acinetobacter baumannii. J. Nanosci. Nanotechnol. 2018, 18, 3806–3815.
Su, C.; Huang, K.; Li, H.H.; Lu, Y.G.; Zheng, D.L. Antibacterial properties of functionalized gold nanoparticles and their application in oral biology. J. Nanomater. 2020, 2020, 5616379.
Raphel, J.; Holodniy, M.; Goodman, S.B.; Heilshorn, S.C. Multifunctional coatings to simultaneously promote osseointegration and prevent infection of orthopaedic implants. Biomaterials 2016, 84, 301–314.
Fisher, L.E.; Hook, A.L.; Ashraf, W.; Yousef, A.; Barrett, D.A.; Scurr, D.J.; Chen, X.; Smith, E.F.; Fay, M.; Parmenter, C.D.; et al. Biomaterial modification of urinary catheters with antimicrobials to give long-term broad spectrum antibiofilm activity. J. Control. Release 2015, 202, 57–64.
Lackner, P.; Beer, R.; Broessner, G.; Helbok, R.; Galiano, K.; Pleifer, C.; Pfausler, B.; Brenneis, C.; Huck, C.; Engelhardt, K.; et al. Efficacy of silver nanoparticles-impregnated external ventricular drain catheters in patients with acute occlusive hydrocephalus. Neurocrit. Care 2008, 8, 360–365.
Taheri, S.; Vasilev, K.; Majewski, P. Silver nanoparticles: Synthesis, antimicrobial coatings, and applications for medical devices. Recent Pat. Mater. Sci. 2015, 8, 166–175.
Ramasamy, M.; Lee, J. Recent nanotechnology approaches for prevention and treatment of biofilm-associated infections on medical devices. BioMed Res. Int. 2016, 2016, 1851242.
O’Neill, J. Analysis and Policy Observatory Tackling Drug-Resistance Infections Globally: Final Report and Recommendations; Government of the United Kingdom: London, UK, 2016. Available online: https://apo.org.au/node/63983 (accessed on 5 November 2021).

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Engineering, Biomedical; Health Care Sciences & Services

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Vishwanath Managuli

View Times: 619

Update Date: 09 Feb 2022

Table of Contents

Video Upload Options

Confirm